Adma Biologics (ADMA) Cash & Equivalents (2011 - 2025)

Adma Biologics' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $87.6 million for Q4 2025.

• Quarterly Cash & Equivalents fell 15.04% year-over-year to $87.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87.6 million (down 15.04% YoY) and the FY2025 annual result came in at $87.6 million, down 15.04% from the prior year.
• Cash & Equivalents was $87.6 million for Q4 2025 at Adma Biologics, up from $61.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $103.1 million in Q4 2024 and bottomed at $34.4 million in Q3 2021.
• A 5-year average of $66.2 million and a median of $65.9 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents sank 42.35% — and 2023, when it jumped 112.57%.
• Adma Biologics' Cash & Equivalents stood at $51.1 million in 2021, then soared by 69.36% to $86.5 million in 2022, then plunged by 40.65% to $51.4 million in 2023, then jumped by 100.86% to $103.1 million in 2024, then dropped by 15.04% to $87.6 million in 2025.
• Business Quant data shows ADMA's Cash & Equivalents at $87.6 million in Q4 2025, $61.4 million in Q3 2025, and $90.3 million in Q2 2025.